PMID- 32087405
OWN - NLM
STAT- MEDLINE
DCOM- 20210201
LR  - 20210201
IS  - 1879-0593 (Electronic)
IS  - 1368-8375 (Linking)
VI  - 103
DP  - 2020 Apr
TI  - Increased DSG2 plasmatic levels identified by transcriptomic-based secretome 
      analysis is a potential prognostic biomarker in laryngeal carcinoma.
PG  - 104592
LID - S1368-8375(20)30028-2 [pii]
LID - 10.1016/j.oraloncology.2020.104592 [doi]
AB  - OBJECTIVES: The tumor secretome deconvolution is a promising strategy to identify 
      diagnostic and prognostic biomarkers. Here, transcriptomic-based secretome 
      analysis was performed aiming to discover laryngeal squamous cell carcinomas 
      (LSCC) biomarkers from potentially secreted proteins (PSPs). MATERIAL AND 
      METHODS: The tumor expression profile (35 LSCC biopsies compared with surrounding 
      normal tissues - SN) revealed 589 overexpressed genes. This gene list was used 
      for secretome analysis based on laryngeal tumors and related secretome databases. 
      RESULTS: Forty-nine (Laryngeal tumor secretome database) and 50 (Human Protein 
      Atlas and Cancer Secretome Database) PSPs presented an association with worse 
      overall survival. Specifically, DSG2 overexpression was strongly correlated with 
      poor survival and distant metastasis. DSG2 increased expression was confirmed in 
      the LSCC dataset (LSCC = 111; SN = 12) from TCGA. A significant association 
      between shorter survival and DSG2 overexpression was also detected. In an 
      independent cohort of cases, we analyzed and confirmed high protein levels of 
      DSG2 in plasma from LSCC patients. CONCLUSION: A set of PSPs including the 
      circulating DSG2, were associated with shorter overall survival in LSCC. DSG2 
      overexpression was also correlated with distant metastasis. The high plasmatic 
      protein levels of DSG2 suggest its potential to be tested in liquid biopsies and 
      applied as prognostic biomarker of LSCC.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Cury, Sarah Santiloni
AU  - Cury SS
AD  - Department of Structural and Functional Biology, Institute of Biosciences, Sao 
      Paulo State University (UNESP), Botucatu, Sao Paulo, Brazil.
FAU - Lapa, Rainer Marco Lopez
AU  - Lapa RML
AD  - Department of Chemical and Biological Sciences, Institute of Biosciences, Sao 
      Paulo State University (UNESP), Botucatu, Sao Paulo, Brazil.
FAU - de Mello, Julia Bette Homem
AU  - de Mello JBH
AD  - Department of Head and Neck Surgery and Otorhinolaryngology, A.C. Camargo Cancer 
      Center, Sao Paulo Brazil.
FAU - Marchi, Fabio Albuquerque
AU  - Marchi FA
AD  - International Research Center, CIPE - A.C. Camargo Cancer Center, Sao Paulo, 
      Brazil.
FAU - Domingues, Maria Aparecida Custodio
AU  - Domingues MAC
AD  - Department of Pathology, Faculty of Medicine, Sao Paulo State University (UNESP), 
      Botucatu, SP, Brazil.
FAU - Pinto, Clovis Antonio Lopes
AU  - Pinto CAL
AD  - Department of Pathology, A.C. Camargo Cancer Center, Sao Paulo, Brazil.
FAU - Carvalho, Robson Francisco
AU  - Carvalho RF
AD  - Department of Structural and Functional Biology, Institute of Biosciences, Sao 
      Paulo State University (UNESP), Botucatu, Sao Paulo, Brazil.
FAU - de Carvalho, Genival Barbosa
AU  - de Carvalho GB
AD  - Department of Head and Neck Surgery and Otorhinolaryngology, A.C. Camargo Cancer 
      Center, Sao Paulo Brazil.
FAU - Kowalski, Luiz Paulo
AU  - Kowalski LP
AD  - Department of Head and Neck Surgery and Otorhinolaryngology, A.C. Camargo Cancer 
      Center, Sao Paulo Brazil.
FAU - Rogatto, Silvia Regina
AU  - Rogatto SR
AD  - Department of Clinical Genetics, University Hospital, Institute of Regional 
      Health Research, University of Southern Denmark, Vejle, Denmark. Electronic 
      address: silvia.regina.rogatto@rsyd.dk.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200219
PL  - England
TA  - Oral Oncol
JT  - Oral oncology
JID - 9709118
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (DSG2 protein, human)
RN  - 0 (Desmoglein 2)
SB  - IM
MH  - Biomarkers, Tumor/*metabolism
MH  - Desmoglein 2/*adverse effects/blood
MH  - Female
MH  - Gene Expression Profiling/*methods
MH  - Humans
MH  - Laryngeal Neoplasms/blood/*diagnosis/pathology
MH  - Male
MH  - Middle Aged
MH  - Prognosis
OTO - NOTNLM
OT  - Biomarker
OT  - Laryngeal squamous cell carcinoma
OT  - Liquid biopsy
OT  - Secretome
OT  - Transcriptome
COIS- Competing interests The authors declare no competing interests.
EDAT- 2020/02/23 06:00
MHDA- 2021/02/02 06:00
CRDT- 2020/02/23 06:00
PHST- 2020/01/13 00:00 [received]
PHST- 2020/02/04 00:00 [accepted]
PHST- 2020/02/23 06:00 [pubmed]
PHST- 2021/02/02 06:00 [medline]
PHST- 2020/02/23 06:00 [entrez]
AID - S1368-8375(20)30028-2 [pii]
AID - 10.1016/j.oraloncology.2020.104592 [doi]
PST - ppublish
SO  - Oral Oncol. 2020 Apr;103:104592. doi: 10.1016/j.oraloncology.2020.104592. Epub 
      2020 Feb 19.